NCT02657928View on ClinicalTrials.gov

Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 8, 2016

Primary Completion Date

May 21, 2018

Study Completion Date

October 7, 2020

Conditions
Estrogen Receptor PositivePostmenopausalRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRecurrent Uterine Corpus Carcinoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Letrozole

Given PO

DRUG

Ribociclib

Given PO

Trial Locations (3)

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER